Triple-Negative Breast Cancer: New Therapy Shows Promise in Blocking Recurrence

A new approach combining targeted therapies with CAR T-cell therapy shows promise in slowing the spread of triple-negative breast cancer, a particularly aggressive form of the disease. Research published recently in Cancer Letters suggests this combination may offer a crucial intervention when other options are limited, potentially controlling cancer recurrence.

Understanding Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) accounts for approximately 10-15% of all breast cancers. It receives this designation since cancer cells lack expression of three common receptors – estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). These receptors are often targets for hormone therapy or HER2-directed therapies, leaving TNBC with fewer standard treatment options. This often leads to poorer prognoses and a higher risk of recurrence. The National Cancer Institute provides comprehensive information on breast cancer types and treatments.

CAR T-Cell Therapy: Harnessing the Immune System

CAR T-cell therapy, or chimeric antigen receptor T-cell therapy, is a type of immunotherapy. It involves engineering a patient’s own T cells – a type of immune cell – to recognize and attack cancer cells. T cells are removed from the patient, genetically modified to express a special receptor (the CAR) that binds to a specific protein on cancer cells, and then infused back into the patient. While CAR T-cell therapy has demonstrated remarkable success in certain blood cancers, its application to solid tumors like breast cancer has proven more challenging. The difficulty lies in the tumor microenvironment and the ability of the engineered T cells to effectively infiltrate and eliminate the cancer.

The Houston Methodist Study: A Synergistic Approach

The recent study, led by Dr. Gabriel Duda, scientific director of transplant oncology and therapeutics at Houston Methodist Research Institute, investigated whether pairing targeted treatments with CAR T-cell therapy could overcome some of these challenges. Researchers found that CAR T-cells were most effective when the remaining cancer burden in distant organs was minimal. This suggests that administering CAR T-cell therapy shortly after surgery or radiation, when microscopic disease may still be present, could be a promising strategy to prevent cancer recurrence. Houston Methodist’s news release details the study’s findings.

Specifically, the research indicated that radiation therapy may enhance the vulnerability of tumors to CAR T-cells. In laboratory and mouse models, the combination of radiation and CAR T-cell therapy slowed tumor growth and reduced the spread of cancer to the lungs and liver. This suggests a potential sequence for treatment: surgical removal of the primary tumor, followed by radiation therapy to address any remaining microscopic disease, and then CAR T-cell therapy to target any lingering cancer cells.

Beyond Breast Cancer: CAR T-Cell Advances in T-Cell Lymphoma

The development of effective CAR T-cell therapies is an active area of research across multiple cancer types. Researchers at Baylor College of Medicine, Texas Children’s Hospital, and Houston Methodist Hospital have also made progress in developing CAR T-cell therapy for T-cell lymphoma, another aggressive cancer. A phase I clinical trial showed early signs of efficacy and a favorable safety profile, with clinical responses observed in 44% of patients. Baylor College of Medicine’s report provides details on this trial.

Dr. Dan G. Duda: A Leader in Transplant Oncology

Dr. Gabriel Duda joined Houston Methodist Hospital in 2025 as the Scientific Director of Transplant Oncology and Therapeutics. His prior research, conducted at Massachusetts General Hospital and Harvard Medical School, focused on tumor interactions with their microenvironments, aiming to identify mechanisms of tumor progression and treatment resistance in gastrointestinal cancers. Houston Methodist’s scholar profile provides a detailed overview of Dr. Duda’s career and research interests.

What So for Patients and Future Research

It’s critical to emphasize that this research is still in its early stages. The findings from laboratory and mouse models need to be validated in larger clinical trials involving human patients. The study does not prove that this combination therapy will be effective for all patients with triple-negative breast cancer, nor does it establish the optimal timing or dosage of the treatments. Though, the results offer a promising new avenue for investigation and potential treatment development.

The study highlights the importance of considering the cancer burden and the tumor microenvironment when designing immunotherapy strategies. The finding that radiation therapy can enhance the effectiveness of CAR T-cells suggests that combining different treatment modalities may be crucial for achieving optimal outcomes.

Next Steps: Clinical Trials and Ongoing Investigation

Researchers are now focused on translating these findings into clinical trials to evaluate the safety and efficacy of this combination therapy in patients with triple-negative breast cancer. These trials will help determine the optimal patient selection criteria, treatment schedule, and potential side effects. Further research will also explore ways to enhance the effectiveness of CAR T-cells and overcome the challenges associated with treating solid tumors. Ongoing surveillance and data analysis will be critical to refining treatment strategies and improving outcomes for patients with this aggressive disease.